Related references
Note: Only part of the references are listed.Colorectal cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Long Non-coding RNA MIR570MG Causes Regorafenib Resistance in Colon Cancer by Repressing miR-145/SMAD3 Signaling
Fang Wei et al.
FRONTIERS IN ONCOLOGY (2020)
Exosomal microRNA in peritoneal fluid as a biomarker of peritoneal metastases from gastric cancer
Hideyuki Ohzawa et al.
ANNALS OF GASTROENTEROLOGICAL SURGERY (2020)
Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma
Michael Teufel et al.
GASTROENTEROLOGY (2019)
Novel Molecular Characterization of Colorectal Primary Tumors Based on miRNAs
Elisa Conde et al.
CANCERS (2019)
First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
A. Carrato et al.
BMC CANCER (2019)
miR-125a-5p Functions as Tumor Suppressor microRNA And Is a Marker of Locoregional Recurrence And Poor prognosis in Head And Neck Cancer
Dat T. Vo et al.
NEOPLASIA (2019)
Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Prashanth Rawla et al.
WORLD JOURNAL OF ONCOLOGY (2019)
Association of differential miRNA expression with hepatic vs. peritoneal metastatic spread in colorectal cancer
Sabine Heublein et al.
BMC CANCER (2018)
Regorafenib suppresses colon tumorigenesis and the generation of drug resistant cancer stem-like cells via modulation of miR-34a associated signaling
Mao-Hua Cai et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
The Impact of miRNA in Colorectal Cancer Progression and Its Liver Metastases
Ovidiu Balacescu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
NOTCH SIGNALING IN DEVELOPMENT, TISSUE HOMEOSTASIS, AND DISEASE
Chris Siebel et al.
PHYSIOLOGICAL REVIEWS (2017)
Identification of a sixteen-microRNA signature as prognostic biomarker for stage II and III colon cancer
Havjin Jacob et al.
ONCOTARGET (2017)
Involvement of Notch-1 in Resistance to Regorafenib in Colon Cancer Cells
Giovanna Mirone et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2016)
MicroRNA as Biomarkers and Diagnostics
Jin Wang et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2016)
Colorectal cancer care in elderly patients: Unsolved issues
Thomas Aparicio et al.
DIGESTIVE AND LIVER DISEASE (2016)
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients
Riccardo Giampieri et al.
SCIENTIFIC REPORTS (2016)
Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013
D. Papamichael et al.
ANNALS OF ONCOLOGY (2015)
miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer
J. Gao et al.
ONCOGENE (2015)
Regulation of microRNA biogenesis
Minju Ha et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
D. W. Miles et al.
BRITISH JOURNAL OF CANCER (2013)
Markers of Response for the Antiangiogenic Agent Bevacizumab
Diether Lambrechts et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score
Martine Extermann et al.
CANCER (2012)
Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment
Bryan P. Schneider et al.
LANCET ONCOLOGY (2012)
Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial
Tim Eisen et al.
LANCET ONCOLOGY (2012)
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
Diether Lambrechts et al.
LANCET ONCOLOGY (2012)
Hypoxia Inducible Factor 1-Alpha (HIF-1 Alpha) Is Induced during Reperfusion after Renal Ischemia and Is Critical for Proximal Tubule Cell Survival
Elisa Conde et al.
PLOS ONE (2012)
Common Polymorphisms in Angiogenesis
Michael S. Rogers et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2012)
Pharmacogenetic Angiogenesis Profiling for First-line Bevacizumab plus Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer
Armin Gerger et al.
CLINICAL CANCER RESEARCH (2011)
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
Scott M. Wilhelm et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study
Arti Hurria et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial
Matthew T. Seymour et al.
LANCET (2011)
Contribution of VEGF polymorphisms to variation in VEGF serum levels in a healthy population
Heba H. Al-Habboubi et al.
EUROPEAN CYTOKINE NETWORK (2011)
Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy
D. H. Kim et al.
ANNALS OF ONCOLOGY (2010)
Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway
Jun Yao et al.
MEDICAL ONCOLOGY (2010)
Complexity of the microRNA repertoire revealed by next-generation sequencing
Lik Wee Lee et al.
RNA (2010)
Microvessel density and the association with single nucleotide polymorphisms of the vascular endothelial growth factor receptor 2 in patients with colorectal cancer
Torben Frostrup Hansen et al.
VIRCHOWS ARCHIV (2010)
γ-Secretase Inhibitors Abrogate Oxaliplatin-Induced Activation of the Notch-1 Signaling Pathway in Colon Cancer Cells Resulting in Enhanced Chemosensitivity
Raymond D. Meng et al.
CANCER RESEARCH (2009)
Gamma-secretase inhibition combined with platinum compounds enhances cell death in a large subset of colorectal cancer cells
Tamara Aleksic et al.
Cell Communication and Signaling (2008)
Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab
Anne M. Schultheis et al.
CLINICAL CANCER RESEARCH (2008)
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
Bryan P. Schneider et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Share Paper
